Onesource Specialty Pharma Q3 FY26 results: Revenue dips, loss widens

Revenue DeclinePat NegativeExceptional ItemRevenue Growth 20pctResults View source PDF Explain this filing

ONESOURCE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-18.9%Reaction day

₹1430.00

prior close

₹1400.00

announcement price

After-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)+0.2%-19.1% vs market

Pharmaceuticals peers, median of 154sector-0.4%-18.5% vs sector

On the reaction day the stock moved 19.1 pts less than Nifty Smallcap 250 and 18.5 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-4.9

10m

-5.5

15m

-5.1

30m

-4.9

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-18.9+0.2-19.1-0.4-18.5

Next day

-18.2+2.1-20.4+0.1-18.3

-22.4+2.1-24.5-0.7-21.7

-14.6+2.9-17.5+0.0-14.6

-15.4+1.3-16.6-0.0-15.3

-17.5+4.2-21.7+2.4-19.8

-19.4+3.9-23.3+1.9-21.3

15d

-9.2+5.1-14.4+1.9-11.2

-5.7+3.7-9.4+0.7-6.4

-0.3-4.3+4.0-8.1+7.8

+27.4+9.1+18.3+3.9+23.5

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 154Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Onesource Specialty Pharma Q3 FY26 standalone revenue fell to Rs 290.22 crores from Rs 375.19 crores QoQ. Standalone loss after tax was Rs 62.19 crores versus a Rs 37.10 crore profit in Q2 FY26. For 9M FY26, standalone revenue grew about 20 percent YoY to Rs 986.42 crores. Consolidated Q3 loss after tax was Rs 88.70 crores on revenue of Rs 290.34 crores. Exceptional items of Rs 7.09 crores relate to employee exits and new labour codes. Auditor Deloitte issued an unmodified review opinion. A contingent claim of USD 136.32 million from Prestige Biopharma remains pending in arbitration.

Likely market impact

Sharp QoQ revenue drop and return to losses in Q3 may pressure the stock. A pending USD 136M Prestige claim is a key risk to watch.